Boehringer Ingelheim and Inflammaso$¥ >me Therapeutics Inc. (Inflammasome) toda€©λ♠y announced they have entered into a '‌‍★co-development and license agreement to develop∞≈↔ up to three therapies for patients with reλ§↕γtinal diseases. By comb↓★ining Inflammasome’s unique intravitreal (↓§IVT) drug delivery technologies with✘  Boehringer Ingelheim’s compounds from its re↓' ™tinal disease pipeline po±&☆rtfolio, Boehringer Ingelheim aim &®≤s to develop novel therapies fo★♦♥r retinal diseases.In 2019§< there were an estimated 82 million patients₽§γ✘ in the seven key co↕σuntries (U.S., Japanγ↓♣™, Germany, U.K., Spain, Italy§ , France) affected by one ®∞↑of the three major forms ♦ ✔of retinal disease: Age related ma☆ $cular degeneration (AMD), diab‍‍etic retinopathy (DR)∞≈ , and diabetic macular↑λ♣✔ edema (DME). Globally, the prevalence r★♠ates of these and other retinal diseases areγ✔ expected to increase over the next‌>♠ 10 years primarily due to aging populations₽π≈ and the global diabetes epide♦&σmic. Despite therapeut↔"☆÷ic advances in some disease areas during the π<¥past years, the real worlα♦₽d results are poor, a εαnd there are no or only limited treatment →↕Ωoptions in many areas, resulting in an ™×¥✔overall high unmet need. The collaboratπ•ion between Boehringer Iσ₽ngelheim and Inflammasome aims to addres≈<s this challenge by using Inflammasom♦ασe’s technology to deli&γver therapeutics in a biode£₹gradable gel formulat"π✔ion into the eye.“We are delight↔≠≥ed to enter into a coπ​✔λllaboration with a company of Boehringer Inge↔ lheim’s stature,” said Paul Ash"✔ton, Chief Executive Officer of Inflammasome The>¶rapeutics. “We look forward to₽  working with their team to lever©πδ→age our respective technologies and experti™¥©se to develop new therπ&σ₽apies for devastating reti§±®&nal diseases leading Ω to blindness. This collaboration fits ou $¥r strategy of advancing÷&¶" the company via bot‌>h collaborations and in♠♥ternal development.”“Boehringer Ingelheim is lo¶ oking forward to developing Inflammasome’s ‍ novel technology for the delivery of our fλ'irst-in- class retinal disease comδ©‍pounds working jointly with Inflammasome’s highγ♥ly experienced scientif♦↓ic team,” said Clive R. Wood, ↕φPhD, Senior Corporate Vice Pres♦'ident, Discovery Research at Bα∞oehringer Ingelheim. “T §φhis will enable us to ' develop a broad range of novel thera÷ εpy options for the many p ♦λσatients with retinal dis₹♠≥eases waiting urgently for bette$π&r and new therapy optio>≥ns.”Boehringer Ingelheimφ←§ takes a holistic appε∑roach in the development of novel retinal d →→σisease therapies, targeting key mechanisms in the£≠✘₩ pathogenesis of retinal diseases. T ←he company has built a comprehenσ₽'÷sive pipeline portfolio ↕↑γof next generation theraφβ↑py approaches in various stages←  of development up to Phase 2ε≈π® in macular degeneration, diabetic retinal¶§∏¥ diseases and beyond. Inflammasome’s nγ₹ovel delivery technology using≈$∑ a long-acting degradable IVT implant comple♦'Ω‌ments this portfolio.Inflammasome i &∞≈s entitled to receiv←★e up to $160 million in up-fr♣α£ont, research and developme>₹≥nt support and milestone gated develo¥‍pment payments as we‌↓≈ll as tiered royalties based on future commerc₽♣σ ial sales of develope™>Ω∑d products and other milestones due on co≠<mmercialization.information source:ph→ ∞arma focus AsiaThe original linα$α₽k:https://www.pharmafocusasia.co♥> ₹m/news/boehringer-ingelheim-partners-with-i®★↓§nflammasome-therapeutics-to-develo€₽p-novel-therapies-for-patients-with-retinal-disea♥✘♣ses2019 Asia-pacific pharma IP Leader Summit:‍♥ http://en.zenseegroup.com/p/510934/will♠≠φ be held in Beijing  on&nb™π→sp;November 14-15, and will attract more than 50♦↓0 industry experts from d₩£™©omestic and foreign pharmaceuti✔ cal companies, biotechnology companies, governmen•¥σ×ts, associations, law firms, intelle↕"≤♠ctual property agents and other companies to ‍•attend.Official regi↓αstration and consultation chann&✔els:Contact：AnnPhone: 021-65650305Email：Mar∞≈™ keting@zenseegroup.comhttp://www.zens∑β≈eegroup.com/forms/view/22113/

iBio, Inc. today announced that it has entered ¥&into the initial Statement of Work (∏&‌£“SOW1”) under its Memorandum of Unde∏$♦™rstanding (“MOU”) with AzarGen Biotech¶<γ∞nologies (Pty.) Ltd. (“Azaδε÷®rGen”).Following iBio’s successful use of ₩≈Ωits technologies and manufacturing♥​₹" capabilities to advance the development'♣ of AzarGen’s surfactant protein therapeut γ♠≥ic through an initial assessmenλπ δt of production feasibility, i∏ n May 2017, the two companies expanded the≠​★ir collaboration by initiating the development o'©f a plant-made rituximab for the SoutΩ h African market under the MOU.Pursuant to the♥↓∏ SOW1, iBio will manufacture resea∑>≤∏rch quantities of a plant-made →↕↓rituximab for AzarGen using iBio’s propri♥↔§etary FastPharming™ System. F∏σollowing batch produc♠™↑¥tion, the drug product candidate wiγ✘¥ll undergo testing via iBiε≤o CDMO’s bioanalytical services.“After demonβ✔★★strating the success of our platfo¥₽₹rm through our opening pro•'ject with AzarGen, we are now advanci₹σng to the next stage of the two compσ×₽¶anies’ collaboration,αβ¥±” commented Robert B. Kay, iBio’s Chai×Ω÷rman and CEO. “We look forward to hel↕☆∏ping AzarGen develop a plant-baseα ™d, bio-similar rituximab product f↓‌or the South African mark‍ σ♦et.”“The early success in αφcombining iBio’s and →&♦εAzarGen's advanced genetic engineering €→&and synthetic biology techniques in plants★♣​  really empowered us to evolve our busines>←s plans and product priorities to i₽¶nitiate development of a biosimilar v£↑ersion of rituximab,” said Dr. Mauritz Venter,‍β CEO of AzarGen. “As we continue to move towaπσ∏βrd the initiation of advanced pre-✔&<clinical activities, we are ™£‍confident that iBio CDMO is ideally ≠§↔ suited to provide us with the requi φ₩±site long-term process deve×₹γ&lopment and cGMP manufacturing support. We ar§×e excited to take this important step f↔∞orward in advancing this program. Focusin<™βg on accessibility and affordabil©"™δity of biological medic←¥ine for the African coγ$>ntinent, we look forward t∞↓∑±o initiating additional proj™™ects with iBio as we p≠®≤rogress.”Rituximab w'™♣÷as first approved by the €→→♣U.S. Food and Drug Administ"σ☆βration in 1997 for treatment of certaiλ♣£n B cell non-Hodgkin lymphomas. Sinc•↑e that time, its clinical uses have expanded to e<$↑♣ncompass treatment of ₩≥→chronic lymphocytic leukemia, "< as well as a range of≠&→' autoimmune diseases, includγΩing certain types of rheumatoid arthritis. "€≤φRituximab has been placed on the World Heal ♣‌‌th Organization’s List of Essential Medicines and•£ it was ranked as one of the world’s to$£p-10 selling pharmaceεγuticals in 2018.2019 Asia-pacπ•&ific pharma IP Leader Summit: http://en.zenseeΩ∏λgroup.com/p/404716/ ‍'<will be held in Beijing  on&δΩ"nbsp;November 14-15, and will attract more than♥≠σ​ 500 industry experts from domes✔£π≈tic and foreign pharmaceutical companies, biotec♦✘hnology companies, gπ$‌overnments, associations, law fir•σσ'ms, intellectual property agents and ≥εother companies to attend.Ofβπ←ficial registration and consultation ch¥δannels:Contact：AnnPhone: 021-65650♦ ♥305Email：Marketing@zenseegroup.comhttp:/♣'™/www.zenseegroup.com/forms/view/22113/